Form 4: Sanara MedTech Controller Granted Restricted Stock

Sanara MedTech Inc. Controller Ashley M. Mackey received a grant of 2,804 restricted common stock shares, vesting over three years.

Summary

• Ashley M. Mackey, Controller of Sanara MedTech Inc. (SMTI), was granted 2,804 shares of common stock.
• The shares are restricted stock granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• The restricted stock will vest in three equal installments on March 22, 2027, March 22, 2028, and March 22, 2029.
• Vesting is contingent upon Ashley M. Mackey's continued employment with the Issuer through each respective vesting date.
• Following this transaction, Ashley M. Mackey beneficially owns a total of 5,067 shares of common stock directly.
• The transaction date for the grant was March 22, 2026, with a transaction price of $0 per share, indicating a grant rather than a purchase.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard executive compensation event, which is generally positive as it aligns management incentives with long-term shareholder value, though it does not reflect operational performance.

Positives

• The grant of restricted stock aligns the Controller's long-term interests with those of shareholders, incentivizing sustained performance.
• This compensation structure serves as a retention mechanism, encouraging the Controller to remain with the company through the vesting periods.

Negatives

• The shares have no immediate cash value or liquidity for the recipient until they vest.
• The vesting is conditional on continued employment, meaning the shares could be forfeited if employment ceases before vesting dates.

Risks

• For the recipient, there is a risk of forfeiture of the unvested shares if employment with Sanara MedTech Inc. terminates prior to the vesting dates.
• For the company, the issuance of these shares upon vesting will result in a minor dilution of existing shareholder equity over time.

Future Outlook

The vesting schedule for the restricted stock indicates a commitment to long-term executive retention and performance alignment through March 2029, contingent on continued employment.

Industry Context

StockSavvy.ai notes that restricted stock grants are a common and effective tool in the healthcare technology sector for executive compensation, designed to align management's long-term interests with shareholder value creation and to ensure executive retention. This practice is consistent with broader industry trends in incentivizing key personnel.

Comparison to Industry Standards

• Restricted stock grants are a standard component of executive compensation packages across various industries, including healthcare technology, often utilized by companies like Medtronic or Stryker to incentivize long-term performance and retention.
• The three-year vesting schedule is typical for such grants, providing a balanced approach to retention and performance incentives, comparable to practices seen at other publicly traded companies in the medical device and biotech sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the Controller's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This type of compensation can serve as a model for incentive programs, potentially boosting morale and retention among key personnel.

Next Steps

• The vesting of the restricted stock will occur in three equal installments on March 22, 2027, March 22, 2028, and March 22, 2029, subject to continued employment.

Key Dates

Keywords

Sanara MedTech, SMTI, Restricted Stock, Executive Compensation, Insider Transaction, Form 4, Stock Grant, Vesting, Controller